TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
September 2023 in “Journal of the American Academy of Dermatology” Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.
December 2025 in “Orvosi Hetilap” Baricitinib is effective and safe for treating alopecia areata.
April 2023 in “Journal of the American Academy of Dermatology” Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.
1 citations
,
April 2024 in “Journal of Dermatological Science” February 2024 in “Cancers” New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.
1 citations
,
November 2023 in “BMC chemistry” Tadalafil and Finasteride may help treat aggressive melanoma.
April 2023 in “Cancer research” KRTAP2-3 could help predict cancer recurrence by identifying specific cancer cells.
March 2026 in “Journal of Pakistan Association of Dermatologists” Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.
1 citations
,
April 2025 in “Clinical Cosmetic and Investigational Dermatology” Erlotinib can cause scalp pustules and hair loss, needing early treatment with antibiotics and steroids.
November 2023 in “Research Portal Denmark” Baricitinib shows promise for severe alopecia areata but isn't a cure and has side effects.
July 2024 in “Journal of Investigative Dermatology” ATR04-484 ointment shows promise for treating skin issues from cancer therapies.
2 citations
,
March 2022 in “Modern Rheumatology Case Reports” A medicine called tofacitinib worked to treat a hair loss condition linked with a muscle and skin disease.
December 2023 in “Journal of ethnopharmacology” Tribuloside can increase skin pigmentation by enhancing melanin production and distribution.
April 2011 in “Cancer Research” 20(S)-Protopanaxadiol-aglycone may help prevent and treat prostate cancer by reducing androgen receptor activity.
45 citations
,
October 2018 in “JCI Insight” Entospletinib effectively prevents eye and skin GVHD in mice.
2 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Baricitinib is a safe and effective treatment for severe alopecia areata.
January 2025 in “The Egyptian Journal of Hospital Medicine” Baricitinib is effective and safe for treating localized vitiligo, alone or with topical tacrolimus.
44 citations
,
October 2009 in “Journal of the American Academy of Dermatology” Topical bexarotene 1% gel might help regrow hair in alopecia areata and is generally safe.
September 2024 in “Journal of the American Academy of Dermatology” PRP treatment may help improve hair density and thickness in breast cancer patients with therapy-induced hair loss.
January 2025 in “Frontiers in Pediatrics” Baricitinib significantly improved hair regrowth and skin condition in a 14-year-old with alopecia areata and atopic dermatitis.
80 citations
,
April 2017 in “Frontiers in Pharmacology” PDRN helps repair tissue and improve wound healing with a high safety profile.
December 2024 in “International Journal of Molecular Sciences” Platelet-rich fibrin may help reduce nonmelanoma skin cancer cell growth.
January 2026 in “Dermatology and Therapy” 1 citations
,
October 2025 in “International Journal of Molecular Sciences” Natural compounds may help treat advanced papillary thyroid cancer by targeting specific molecular pathways.
November 2022 in “bioRxiv (Cold Spring Harbor Laboratory)” Prostaglandin E2 helps prevent hair loss from radiotherapy by protecting hair cells.
November 2025 in “Journal of Cutaneous Medicine and Surgery” JAK inhibitors are effective and safe for treating severe alopecia areata.
1 citations
,
January 2025 in “Annals of Dermatology” Baricitinib is effective and safe for treating alopecia areata in Korea.
January 2024 in “Wiadomości Lekarskie” The ABI1 gene contributes to prostate cancer progression and treatment resistance.